Ariad Pharma (ARIA) Misses Q4 EPS, Revenue Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $24.07 --0%
Financial Fact:
Income (loss) from operations: -24.99M
Today's EPS Names:
OMID, SICP, SCKT, More
Financial Fact:
Income (loss) from operations: -24.99M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Ariad Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.38), $0.19 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $78 thousand versus the consensus estimate of $940 thousand.
For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.
For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- AMD stock rallies on expanded Meta AI infrastructure deal and broader chip rally
- Top E&C stocks to watch ahead of Q3 earnings, says Citi
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
